T lymphocytes as therapeutic arsenal for patients with hematological malignanciesMontoro, Juana; Piñana, José L.a,b; Sanz, Jaimea,b; Guerreiro, ManuelaCurrent Opinion in Oncology: November 2018 - Volume 30 - Issue 6 - p 425–434 doi: 10.1097/CCO.0000000000000481 HEMATOLOGIC MALIGNANCIES: Edited by Miguel A. Sanz Abstract Author InformationAuthors Article MetricsMetrics Purpose of review We present an overview of the clinically available immunotherapeutic platforms centered on T cell lymphocytes for the treatment of hematological malignancies with a special focus on the advances achieved since 2017. Recent findings The most promising strategies of T cell therapies are based on the infusion of unmanipulated donor lymphocytes, antigen-specific T cells, ex-vivo genetically modified T cells or in-vivo manipulation of T cells using antibodies (bispecific and checkpoint inhibitors). To select the most appropriate option for a specific patient, is important to understand not only each platform-specific biological mechanisms, clinical activity and toxicities but also their intrinsic differences. In this extremely fast-growing field, to keep track of recent advances is a hard and challenging task for a hematologist. Therefore, we aimed to provide a global integrative review of T-cell-based immunotherapies, essential to ascertain their optimal place and timing in our daily clinical practice. Summary We highlight recent advances and discuss future directions of T-cell-based immunotherapies entering the common clinical practice in hematology. aTransplant Unit, Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia bCIBERONC, Instituto de Salud Carlos III, Madrid, Spain Correspondence to Manuel Guerreiro, Transplant Unit, Department of Hematology, Hospital Universitario y Politécnico La Fe, Avenida Fernando Abril Martorell 106, 46026 Valencia, Spain. Tel: +34 961 24 58 75; fax: +34 961 24 62 01; e-mail: email@example.com Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.